Clinical trialNCT04429191UnknownPhase 1Interventional

JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation

SponsorJasper Therapeutics, Inc.Enrollment40ACUTE MYELOID LEUKEMIA; AMLMYELODYSPLASTIC SYNDROME; MDS

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase 1a/b study to evaluate the safety and tolerability of an antibody conditioning regimen known as JSP191, in combination with low dose radiation and fludarabine, in subjects with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) undergoing allogenic blood stem cell transplantation.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Andrew Artz, MD,MS
City of Hope Medical Center
Principal Investigator
clinicaltrials.gov ↗
Ankur Varma, MD,PhD
Rush University Medical Center
Principal Investigator
clinicaltrials.gov ↗
Arpita Gandhi, MD
Oregon Health and Science University
Principal Investigator
clinicaltrials.gov ↗
Bart Scott, MD
Fred Hutchinson Cancer Center
Principal Investigator
clinicaltrials.gov ↗
Catherine Lee, MD
Huntsman Cancer Institute
Principal Investigator
clinicaltrials.gov ↗
Lori Muffly, MD,MS
Stanford University
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

City of Hope Comprehensive Cancer Center
Duarte, California, United States
Recruiting
Stanford University
Stanford, California, United States
Recruiting
Rush University Medical Center
Chicago, Illinois, United States
Recruiting
Oregon Health & Science University
Portland, Oregon, United States
Recruiting
Huntsman Cancer Institute - University of Utah
Salt Lake City, Utah, United States
Recruiting
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Humanized anti-CD117 Monoclonal Antibody

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 8 Jul 2020
Primary completion: 15 Oct 2023
Completion: 8 Dec 2023
Last update posted: 11 Jun 2021
Registered enrollment: 40
Registry id: NCT04429191

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.